| ABIVAX SA EO -,01 |
| Frankreich |
| Gesundheit |
| FR0012333284 / A14UQC |
| 2X1 (Frankfurt) |
| FRA:2X1, ETR:2X1, 2X1:GR |
| - |
| https://www.abivax.com/ |
|
Abivax SA is a France-based clinical-stage biotechnology company dedicated to developing innovative therapeutics that modulate the immune response in patients with chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms, ..
>Volltext.. |
| 7654.62 Mio. EUR |
| 7155.87 Mio. EUR |
| - |
| -250.08 Mio. EUR |
| -336.81 Mio. EUR |
| -4.75 EUR |
| 32.16 Mio. EUR |
| 517.77 Mio. EUR |
| -162.43 Mio. EUR |
| 8.42 |
| - |
| -264.35% |
| - |
| - |
| - |
| - |
| ABIVAX |
| 04.05.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|